LONDON, Feb 10 (Reuters) - Some lymphoma patients who keep taking Genentech Inc and Biogen Idec's Rituxan after chemotherapy live 40 percent longer than those who stop taking the drug, Israeli ...
Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2 DLBCL is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results